Topic: translational research
Deerfield Management and Harvard University are setting up a new company dubbed Lab1636, with $100 million in backing from Deerfield.
The move sees Saha end his near-10-year spell away from Big Pharma for the chance to run Bristol-Myers’ translational medicine operation.
Francis Collins remains NIH chief, but billions of dollars in cuts could be on the way.
Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical trials of new cancer medicines.
A trio of pharmas have bought into the vision of early startup Blade Therapeutics. Pfizer Venture Investments, Novartis Institutes for Biomedical Research and Bristol-Myers Squibb all came in to the $45 million Series B round for the startup, which aims to address novel targets in fibrotic disease. It expects to get into the clinic with this financing